Dashboard
LoginSign Up

Financial News

asianewsnetwork112d ago

Response to the Budget 2026/2027 by Cushman & Wakefield

Response to the Budget 2026/2027 by Cushman & Wakefield Asia News Network (ANN) is the leading regional alliance of news titles striving to bring the region closer, through an active sharing of editorial content on happenings in the region.

#ECONOMY
“Red Gold” Rush: 3 Copper Stocks Powering the AI Boom
fool_ca112d ago

“Red Gold” Rush: 3 Copper Stocks Powering the AI Boom

A red gold rush is underway in 2026 with three Canadian mining powerhouses expected to power the AI boom.The post “Red Gold” Rush: 3 Copper Stocks Powering the AI Boom appeared first on The Motley Fool Canada.

#STOCKS#COMMODITIES
Still awaiting those promised jobs
trinidadexpress112d ago

Still awaiting those promised jobs

After months of waiting, thousands of our citizens are still hoping to receive some type of positive news concerning those 20,000 jobs that were said to be supposedly available and that they were selected to fill one of the vacancies.

#ECONOMY
Wagin Woolorama contributes greatly: Shire President
thewest112d ago

Wagin Woolorama contributes greatly: Shire President

Shire of Wagin president Phil Blight said Wagin Woolorama was a major contributor to the community and would benefit greatly from a substantial $300,000 grant directed at the next three years.

#ECONOMY
Citizens feeling early governance gaps
trinidadexpress112d ago

Citizens feeling early governance gaps

The UNC Government has now been in office for ten months and, while this is not a significant span of time, the performance in the early period of its tenure gives an indication of its approach to administration and governance.

#ECONOMY
globenewswire_fr112d ago

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its upsized underwritten public offering of 20,000,000 shares of its common stock at a price to the public of $5.00 per share. The aggregate gross proceeds to Larimar from this offering are expected to be $100 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Larimar has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Larimar. The offering is expected to close on or about February 27, 2026, subject to the satisfaction of customary closing conditions.

#STOCKS